New drug combo targets Hard-to-Treat cancers

NCT ID NCT06724016

Recruiting now Disease control Sponsor: Hanmi Pharmaceutical Company Limited Source: ClinicalTrials.gov ↗

First seen Nov 20, 2025 · Last updated May 17, 2026 · Updated 22 times

Summary

This early-phase study tests an experimental drug called HM16390, given alone or with the immunotherapy pembrolizumab, in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to find safe doses and check for early signs of tumor shrinkage. About 292 adults will take part across multiple centers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Asan Medical Center
ACTIVE_NOT_RECRUITING

Seoul, 05505, South Korea
Karmanos Cancer Institute
NOT_YET_RECRUITING

Detroit, Michigan, 48201, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Seoul National University Bundang Hospital
RECRUITING

Seongnam-si, Gyeonggi-do, 13620, South Korea
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea
Severance Hospital
RECRUITING

Seoul, 03722, South Korea

Conditions

Explore the condition pages connected to this study.

ADVANCED OR METASTATIC SOLID TUMORS